ARWR ARROWHEAD PHARMACEUTICALS IN
2026Q1 · CUSIP 04280A100 · Sector: Healthcare & Biotech
Lit · Institutions accelerating in
Holders
432
Δ holders QoQ
+30
Breadth percentile
Top 10%
Whale holders
200
Δ whales
+10
Inst. holding value
$7.5B
New positions
103
Closed positions
73
Price momentum (1Q)
+16.1%
Put / Call
11/13
Breadth history (34 quarters)
Past Lit Events & Aftermath 15 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2026Q1 | Top 10% | — | — |
| 2025Q4 | Top 4% | +16.1% | — |
| 2025Q3 | Top 14% | +59.1% | +92.1% |
| 2025Q2 | Top 16% | +107.2% | +223.4% |
| 2023Q2 | Top 14% | -5.4% | +2.1% |
| 2021Q2 | Top 12% | +21.8% | -18.0% |
| 2020Q4 | Top 12% | -16.4% | -30.5% |
| 2019Q4 | Top 6% | -5.7% | +12.7% |
Options Sentiment
Put holders
11
QoQ: +3
Call holders
13
QoQ: -1
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-2.08
EPS YoY
—
Revenue (TTM)
$0.6B
Revenue YoY
+14.1%
Net margin
-48.4%
ROE
-49.0%
Debt ratio
72.9%
FCF (TTM)
-$51M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.